Idiopathic intracranial hypertension (IIH) has been very rarely reported in patients treated with mesalazine. Following a recent review, warnings for IIH are being added to the product information for all mesalazine products.
Similar Posts
Field Safety Notices: 19 to 23 January 2026
List of Field Safety Notices from 19 to 23 January 2026.
Research: Digital mental health technology: user and public perspectives on identifying and reporting harms
A research report on attitudes regarding identifying and reporting harms associated with the use of DMHT and awareness of the MHRA Yellow Card Scheme.
MHRA Safety Roundup: July 2025
Summary of the latest safety advice for medicines and medical device users
Decision: Advertising Investigations: December 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Apply for manufacturer or wholesaler of medicines licences
How to apply for, update and cancel licences for the manufacture, import and wholesale of human and veterinary medicines.
Class 2 Medicines Recall: Syri Limited, T/A SyriMed, Baclofen 10mg/5ml Oral Solution, EL(26)A/06
Syri Limited, T/A SyriMed is recalling batches of product as a precautionary measure due to crystallisation observed over time in the oral solution.